News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
772,837 Results
Type
Article (55720)
Company Profile (490)
Press Release (716626)
Multimedia
Podcasts (123)
Webinars (16)
Section
Business (220096)
Career Advice (2894)
Deals (37988)
Drug Delivery (122)
Drug Development (87615)
Employer Resources (185)
FDA (17443)
Job Trends (16276)
News (374076)
Policy (36365)
Tag
Academia (2928)
Academic (1)
Accelerated approval (12)
Adcomms (30)
Allergies (106)
Alliances (54141)
ALS (120)
Alzheimer's disease (1558)
Antibody-drug conjugate (ADC) (183)
Approvals (17401)
Artificial intelligence (359)
Autoimmune disease (34)
Automation (19)
Bankruptcy (393)
Best Places to Work (12335)
BIOSECURE Act (20)
Biosimilars (134)
Biotechnology (347)
Bladder cancer (100)
Brain cancer (39)
Breast cancer (388)
Cancer (3059)
Cardiovascular disease (244)
Career advice (2434)
Career pathing (34)
CAR-T (202)
CDC (38)
Cell therapy (548)
Cervical cancer (23)
Clinical research (71758)
Collaboration (1102)
Company closure (3)
Compensation (703)
Complete response letters (33)
COVID-19 (2858)
CRISPR (67)
C-suite (357)
Cystic fibrosis (120)
Data (3081)
Decentralized trials (2)
Denatured (41)
Depression (76)
Diabetes (370)
Diagnostics (6816)
Digital health (24)
Diversity (10)
Diversity, equity & inclusion (46)
Drug discovery (153)
Drug pricing (148)
Drug shortages (33)
Duchenne muscular dystrophy (136)
Earnings (91419)
Editorial (48)
Employer branding (23)
Employer resources (160)
Events (123686)
Executive appointments (906)
FDA (19161)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (997)
Gene editing (146)
Generative AI (28)
Gene therapy (426)
GLP-1 (901)
Government (5023)
Grass and pollen (6)
Guidances (181)
Healthcare (20303)
HIV (43)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (180)
Immuno-oncology (11)
Indications (40)
Infectious disease (3047)
Inflammatory bowel disease (164)
Inflation Reduction Act (13)
Influenza (69)
Intellectual property (124)
Interviews (556)
IPO (17359)
IRA (55)
Job creations (4377)
Job search strategy (2005)
Kidney cancer (15)
Labor market (52)
Layoffs (568)
Leadership (26)
Legal (9021)
Liver cancer (85)
Longevity (12)
Lung cancer (430)
Lymphoma (215)
Machine learning (11)
Management (63)
Manufacturing (421)
MASH (98)
Medical device (14219)
Medtech (14224)
Mergers & acquisitions (21350)
Metabolic disorders (939)
Multiple sclerosis (103)
NASH (23)
Neurodegenerative disease (138)
Neuropsychiatric disorders (41)
Neuroscience (2304)
NextGen: Class of 2025 (7292)
Non-profit (4921)
Now hiring (47)
Obesity (479)
Opinion (277)
Ovarian cancer (104)
Pain (121)
Pancreatic cancer (124)
Parkinson's disease (198)
Partnered (22)
Patents (316)
Patient recruitment (172)
Peanut (55)
People (63314)
Pharmaceutical (112)
Pharmacy benefit managers (24)
Phase I (22297)
Phase II (31458)
Phase III (23518)
Pipeline (1695)
Policy (235)
Postmarket research (2989)
Preclinical (9645)
Press Release (71)
Prostate cancer (150)
Psychedelics (46)
Radiopharmaceuticals (276)
Rare diseases (520)
Real estate (6650)
Recruiting (73)
Regulatory (25040)
Reports (51)
Research institute (2600)
Resumes & cover letters (456)
Rett syndrome (10)
RNA editing (10)
RSV (54)
Schizophrenia (98)
Series A (172)
Series B (117)
Service/supplier (14)
Sickle cell disease (67)
Special edition (22)
Spinal muscular atrophy (160)
Sponsored (35)
Startups (3990)
State (2)
Stomach cancer (17)
Supply chain (83)
Tariffs (65)
The Weekly (80)
Vaccines (883)
Venture capital (58)
Weight loss (314)
Women's health (50)
Worklife (20)
Date
Today (94)
Last 7 days (385)
Last 30 days (1940)
Last 365 days (32943)
2025 (17840)
2024 (37312)
2023 (42074)
2022 (53380)
2021 (58050)
2020 (56802)
2019 (50097)
2018 (37941)
2017 (35109)
2016 (35048)
2015 (41124)
2014 (35331)
2013 (30699)
2012 (32649)
2011 (33128)
2010 (31429)
Location
Africa (953)
Alabama (69)
Alaska (7)
Arizona (262)
Arkansas (14)
Asia (44905)
Australia (7875)
California (7707)
Canada (2409)
China (719)
Colorado (333)
Connecticut (342)
Delaware (199)
Europe (99153)
Florida (1140)
Georgia (255)
Hawaii (1)
Idaho (63)
Illinois (701)
India (30)
Indiana (378)
Iowa (18)
Japan (237)
Kansas (113)
Kentucky (32)
Louisiana (15)
Maine (64)
Maryland (1088)
Massachusetts (5845)
Michigan (255)
Minnesota (474)
Mississippi (3)
Missouri (99)
Montana (31)
Nebraska (25)
Nevada (81)
New Hampshire (72)
New Jersey (2160)
New Mexico (31)
New York (2156)
North Carolina (1201)
North Dakota (9)
Northern California (3353)
Ohio (241)
Oklahoma (16)
Oregon (41)
Pennsylvania (1649)
Puerto Rico (18)
Rhode Island (39)
South America (1338)
South Carolina (35)
South Dakota (1)
Southern California (2870)
Tennessee (129)
Texas (1167)
United States (28883)
Utah (228)
Virginia (204)
Washington D.C. (78)
Washington State (670)
West Virginia (4)
Wisconsin (82)
772,837 Results for "melinta therapeutics formerly known as rib x pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners
June 16, 2025
·
6 min read
Press Releases
Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage Products
October 17, 2024
·
3 min read
Press Releases
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.
July 3, 2025
·
7 min read
Pharm Country
Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam
Venatorx Pharmaceuticals (Venatorx) and Melinta Therapeutics (Melinta) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for cefepime-taniborbactam.
February 23, 2024
·
12 min read
Pharm Country
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.
Melinta Therapeutics LLC and Venatorx Pharmaceuticals, Inc., announced that they have entered into a License Agreement to facilitate a strategic partnership in the U.S. to commercialize cefepime-taniborbactam, a beta-lactam / beta-lactamase inhibitor combination antibiotic being developed for the treatment of complicated urinary tract infections and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults.
November 9, 2023
·
13 min read
Drug Development
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris.
May 23, 2024
·
4 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
June 12, 2025
·
5 min read
Press Releases
Melinta Joins NHIA Future of Infusion Advisory Council
December 2, 2024
·
3 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida
May 21, 2025
·
4 min read
1 of 77,284
Next
